Quantifying the ease of viral escape from broad and narrow antibodies to influenza hemagglutinin

Michael B. Doud\textsuperscript{1,2,3,†}, Juhye M. Lee\textsuperscript{1,2,3,†}, and Jesse D. Bloom\textsuperscript{1,2,*}

\textsuperscript{1}Basic Sciences and Computational Biology Program, Fred Hutchinson Cancer Research Center
\textsuperscript{2}Department of Genome Sciences and \textsuperscript{3}Medical Scientist Training Program, University of Washington
Seattle, WA, USA
\textsuperscript{†}These authors contributed equally
\textsuperscript{*}Correspondence: jbloom@fredhutch.org

SUMMARY

Influenza virus can completely escape most antibodies with single mutations. However, rare antibodies broadly neutralize many viral strains. It is unclear how easily influenza virus might escape such antibodies if they became widespread due to therapeutic use or vaccination. Here we map all single amino-acid mutations that increase resistance to broad antibodies targeting an H1 hemagglutinin. Crucially, our approach not only identifies antigenic mutations but also quantifies their effect sizes. All antibodies select mutations, but the effect sizes vary widely. The virus can escape a broad antibody targeting hemagglutinin's receptor-binding site the same way it escapes narrow strain-specific antibodies: via single mutations with huge effects. In contrast, broad antibodies targeting hemagglutinin's stalk only select mutations with small effects. Therefore, antibody breadth is not necessarily an indicator of the difficulty of viral escape. Broadly neutralizing antibodies targeting hemagglutinin's stalk are quantifiably harder to escape than the other antibodies tested here.

INTRODUCTION

Nearly all viruses show some antigenic variation. However, the extent of this variation ranges widely. For instance, although both measles virus (Birrer et al., 1981; Ter Meulen et al., 1981) and polio virus (Crainic et al., 1983; Diamond et al., 1985; Drexler et al., 2014) exhibit antigenic variation, the magnitude of this variation is small. Therefore, immunity to these viruses is lifelong (Panum, 1847; Salk, 1984). In contrast, human influenza virus exhibits much more antigenic variation. So although
infection with an influenza virus strain provides long-term immunity to that exact strain (British Medical Journal, 1978; Davies et al., 1982; Yu et al., 2008), the virus’s rapid antigenic evolution erodes the effectiveness of this immunity to that strain’s descendants within four to seven years (Couch and Kasel, 1983).

One possible reason that viruses exhibit different amounts of antigenic variation is that they have disparate evolutionary capacities to escape the immunodominant antibodies generated by natural immune responses (Lipsitch and O’Hagan, 2007; Cobey, 2014; Fulton et al., 2015). According to this explanation, human influenza virus undergoes rapid antigenic drift because most neutralizing antibodies target epitopes on the viral hemagglutinin (HA) protein that are highly tolerant of mutational change. This explanation is supported by classic experiments showing that it is easy to select viral mutants that escape most antibodies (Yewdell et al., 1979; Webster and Laver, 1980), as well as by the observation that mutations that alter antigenicity arise frequently during influenza’s evolution globally (Koel et al., 2013; Chambers et al., 2015; Petrie et al., 2016; Neher et al., 2016) and within individual humans with long-term infections (Xue et al., 2017). A corollary of this explanation is that influenza virus’s capacity for antigenic drift would be reduced if most antibodies instead targeted epitopes that were less mutationally tolerant.

Verifying this corollary has become of practical importance with the discovery of broadly neutralizing antibodies against influenza virus. These antibodies typically target conserved epitopes in HA’s stalk (Sui et al., 2009; Ekiert et al., 2009; Corti et al., 2011) or receptor-binding site (Lee et al., 2012; Ekiert et al., 2012; Schmidt et al., 2015), and neutralize a wide range of viral strains. Broad antibodies are usually less abundant in human serum than antibodies to antigenically variable epitopes on the head of HA (Ellebedy et al., 2014; Andrews et al., 2015). However, major efforts are underway to elicit broad antibodies by vaccination or administer them directly as therapeutics (Krammer and Palese, 2015; Corti et al., 2017).

If these efforts succeed, the epitopes of broad antibodies will be under strong antigenic selection in human influenza virus. Might such selection then drive antigenic variation in these epitopes? There is precedent for the idea that the immune status of the host population can shape influenza virus evolution: the virus undergoes faster antigenic drift in long-lived humans that accumulate immune memory than in short-lived swine that are mostly naive (Sheerar et al., 1989; Luoh et al., 1992), and poultry vaccination may accelerate antigenic drift of avian influenza (Lee et al., 2004; Cattoli et al., 2011). But alternatively, perhaps broad antibodies are broad because the virus has difficulty escaping them regardless of selection from host immunity.
So far, there is limited data to distinguish between these possibilities. Several studies have shown that the head domain of HA is more mutationally tolerant than the stalk domain where many broad antibodies bind (Thyagarajan and Bloom, 2014; Wu et al., 2014; Heaton et al., 2013). However, these studies did not select for antibody escape, so it is difficult to relate their measurements to the virus’s evolutionary capacity under immune selection. Other work has shown that it is possible to select antigenic mutants with broad antibodies (Yoshida et al., 2009; Chai et al., 2016), demonstrating that these epitopes are not entirely refractory to change. But given that antibodies can select some antigenic variation even in measles virus (Birrer et al., 1981; Ter Meulen et al., 1981) and polio virus (Crainic et al., 1983; Diamond et al., 1985), the existence of selectable mutations does not necessarily imply that influenza virus can escape broad antibodies as easily as it drifts away from narrow strain-specific ones. The fundamental problem is that existing studies have not quantified the ease of viral escape in a way that can be compared across antibodies in an apples-to-apples fashion.

Here we systematically quantify the results of selecting all single amino-acid mutations to an H1 HA with several broad and narrow antibodies. Critically, our approach quantifies the magnitude of the antigenic effect of every mutation in a way that can be directly compared across antibodies. We find that even the broadest antibodies select antigenic mutations. However, the magnitudes of the antigenic effects vary greatly across antibodies. Single mutations make the virus completely resistant to both narrow strain-specific antibodies and a broad antibody against the receptor-binding site. But no single mutation does more than modestly increase the virus’s resistance to two broad antibodies against the HA stalk. Therefore, broad anti-stalk antibodies are quantifiably more resistant to viral escape via single amino-acid mutations than the other antibodies tested here.

RESULTS

An approach to quantify the fraction of virions with each mutation that escape antibody neutralization

We can visualize the outcome of antibody selection on viral populations containing antigenic mutations as in Figure 1. If a mutation strongly escapes neutralization, then all virions with this mutation survive antibody treatment at a concentration where other virions are mostly neutralized (Figure 1A). This escape is manifested by a large shift in the neutralization curve for the mutant (Figure 1B). If we draw vertical lines
Figure 1: Quantifying the fraction of virions with each mutation that escape antibody neutralization. This figure shows hypothetical data for four viral variants. (A) Virions with the V1K mutation (orange) completely survive an antibody concentration where most other virions are neutralized. (B) This resistance is manifested by a large shift in V1K’s neutralization curve. (C) For each dotted vertical line drawn through the neutralization curves in (B), we calculate the fraction of virions with that mutation that survive the antibody, and indicate this fraction by the height of the letter corresponding to that amino acid at that site. (D-F) Similar data to the first three panels, but now V1K has only a small antigenic effect, and so only modestly increases the fraction of virions that survive antibody treatment.

through the overlaid neutralization curves, we can calculate the fraction of virions with each mutation that survive neutralization at each antibody concentration. These fractions can be represented using logo plots, where the height of each letter is proportional to the fraction of virions with that amino acid at a site that survive (Figure 1C). Large letters correspond to strong escape mutations.

Now consider the case where a mutation has just a small antigenic effect, and so only slightly increases the fraction of virions that survive neutralization (Figure 1D). In this scenario, the neutralization curve shifts only slightly (Figure 1E). In the logo plot representation, the antigenic mutation is only slightly larger than other amino acids (Figure 1F), since possessing the mutation only modestly increases the chance that a virion survives antibody treatment. These logo plots therefore provide a way to both identify antigenic mutations and quantify the magnitudes of their effects in a way that is directly comparable across antibodies.

Our goal is to determine the fraction of mutant virions that survive antibody neu-
ralization for all mutations to HA. One way to do this would be to measure individual neutralization curves for each of the $19 \times 565 = 10,735$ single amino-acid mutants of the 565-residue HA protein. However, individually creating and assaying that many mutants would be exceedingly time-consuming and expensive. Fortunately, we have shown that antibody selection on all viral mutations can be assayed in a single experiment using mutational antigenic profiling (Doud et al., 2017; Dingens et al., 2017). This approach involves generating viral libraries containing all mutations to the protein of interest, selecting these viruses with or without antibody, and using an accurate deep-sequencing method to determine the relative frequencies of each mutation.

These frequencies can be analyzed to calculate the fraction of virions with each mutation that survive antibody treatment. Specifically, the deep sequencing determines the frequencies of virions carrying amino-acid $a$ at site $r$ in the antibody-selected and mock-selected conditions, which we denote as $\rho_{r,a}^{\text{selected}}$ and $\rho_{r,a}^{\text{mock}}$, respectively. We can also measure the total fraction of the viral library that survives the antibody, which we denote as $\gamma$. The fraction of variants with amino-acid $a$ at site $r$ that survive antibody selection is then simply

$$F_{r,a} = \gamma \times \frac{\rho_{r,a}^{\text{selected}}}{\rho_{r,a}^{\text{mock}}}.$$  

(1)

For instance, in Figure 1A, the frequency of virions with the orange mutation is $\rho_{r,a}^{\text{selected}} = \frac{4}{7}$ in the antibody selection and $\rho_{r,a}^{\text{mock}} = \frac{4}{16}$ in the mock selection. The overall fraction of virions that survive the antibody in Figure 1A is $\gamma = \frac{7}{16}$. Therefore, we use Equation 1 to calculate that the fraction of variants with the orange mutation that survive is $F_{r,a} = \frac{7}{16} \times \frac{4/7}{4/16} = 1$. Performing the analogous calculation for Figure 1D correctly determines that fraction of virions with the orange mutation that survive the antibody is only 0.5 for the scenario in that figure panel. In the analyses of real data below, we will plot the excess fraction surviving above the overall library average, which is

$$F_{r,a}^{\text{excess}} = \max(0, F_{r,a} - \gamma).$$  

(2)

Details of how the calculations are extended to account for sequencing errors and sampling statistics are in the METHODS. Open-source software that performs all steps in the analysis beginning with the deep sequencing data is available at [https://jbloomlab.github.io/dms_tools2/](https://jbloomlab.github.io/dms_tools2/).
Figure 2: Epitopes and breadth of broad and narrow antibodies targeting HA. (A) Crystal structures of the broad antibodies and sites of escape mutations selected by the narrow ones superimposed on the structure of the HA trimer (PDB 1RVX; Gamblin et al., 2004). S139/1 (PDB 4GMS; Lee et al., 2012) targets the receptor-binding site; C179 (PDB 4HLZ; Dreyfus et al., 2013) and F16v3 (PDB 3ZTN; Corti et al., 2011) target the stalk. The sites of escape mutations for H17-L19, H17-L10, and H17-L7 are those mapped by Doud et al. (2017). (B) A phylogenetic tree of HA subtypes. Circles (broad antibodies) and squares (narrow antibodies) denote reported antibody binding or neutralization activity against that subtype. Not all antibodies have been tested against all subtypes.

Broad and narrow antibodies that neutralize influenza virus

We applied this approach to anti-HA antibodies with a range of breadths and epitopes. The crystal structures or sites of escape mutations selected by these antibodies are shown in Figure 2A. We chose two broad antibodies, F16v3 and C179, that target the stalk of HA (Corti et al., 2011; Okuno et al., 1993; Dreyfus et al., 2013). F16v3 is extremely broad, and neutralizes both group 1 and group 2 HAs (Figure 2B). C179 is less broad, and neutralizes only some group 1 HAs (Figure 2B). We also selected a broad antibody, S139/1, that targets HA’s receptor-binding site and can neutralize both group 1 and group 2 HAs (Yoshida et al., 2009; Lee et al., 2012). Finally, we re-analyzed deep sequencing data from prior mutational antigenic profiling of three narrow strain-specific antibodies, H17-L19, H17-L10, and H17-L7 (Doud et al., 2017). These narrow antibodies bind the Ca2, Ca1, and Cb antigenic regions on HA’s globular
Figure 3: Neutralization of wildtype virus by each antibody, and the fraction of mutant library virions surviving at each concentration used in our experiments. The curves show neutralization of the wildtype A/WSN/1933 virus. Each point represents the mean and standard deviation of three measurements. The vertical dotted lines show the concentrations of antibody that were then used in the mutant virus library selections, and the tables give the overall fraction of the mutant virus libraries that survived at each concentration, determined by qRT-PCR.

head (Caton et al., 1982), and only neutralize a narrow slice of H1 viruses.

We performed our experiments using the A/WSN/1933 (H1N1) strain of influenza, which is neutralized by all six antibodies (Figure 3). We used antibody concentrations sufficient for nearly complete neutralization of wildtype virus, allowing us to detect antigenic mutations that increase the fraction of mutant virions surviving beyond the baseline of wildtype (Figure 3). We used several concentrations of each broad antibody to increase sensitivity to antigenic mutations of both large and small effect.

Quantifying the antigenic effects of all mutations selected by each antibody

We performed mutational antigenic profiling using the three broad antibodies at the concentrations indicated in Figure 3, and calculated the fraction of virions carrying each mutation that survived neutralization. All experiments were performed in full biological triplicate using three independently generated virus libraries carrying sin-
Figure 4: Strain-specific and anti-receptor-binding-site antibodies select mutations with large antigenic effects, but anti-stalk antibodies only select small-effect mutations. The excess fraction of virions with a mutation at each site that survive the antibody, averaging across all amino-acid mutations at each site (see Equation 10). There are multiple sites of large-effect mutations for H17L19, H17L10, H17L7, and S139/1 – but none for FI6v3 and C179. Figure S2 shows the excess fraction surviving for the largest-effect mutation at each site. Figures S3, S4, S5, S6, S7, and S8 show all mutations using logo plots. Sites are labeled in H3 numbering.
gle amino-acid mutations to HA (Doud and Bloom, 2016). The correlations among replicates are shown in Figure S1. For the remainder of this paper, we will refer to the median antigenic effect of each mutation across replicates.

It is immediately obvious that the narrow strain-specific antibodies and the antibody targeting HA's receptor-binding pocket (S139/1) select mutations with large antigenic effects. For all four of these antibodies, there are multiple sites in HA where mutations enable a substantial fraction of virions to survive high antibody concentrations (Figure 4). Specifically, there are mutations that enable over a third of virions to survive at concentrations where virtually all wildtype virions are neutralized (Figure S2). Therefore, the virus can escape these four antibodies with the sort of large-effect single amino-acid mutations that characterize traditional influenza antigenic drift (Yewdell et al., 1979; Webster and Laver, 1980; Koel et al., 2013; Chambers et al., 2015; Petrie et al., 2016; Neher et al., 2016).

In contrast, the stalk-targeting antibodies C179 and FI6v3 select no strong escape mutants. If we look at the results for these antibodies on the same scale as the other antibodies, we see only a few small bumps in the fraction of virions surviving (Figures 4 and S2). Only if we zoom in can we see that there are actually a few sites where mutations slightly increase the fraction of virions surviving C179 and FI6v3 (Figures S3, S4, S5, S6, S7, and S8). But the effect sizes of these antigenic mutations are tiny compared to the other antibodies – especially for FI6v3. Therefore, the HA of A/WSN/1933 influenza virus is far less capable of escaping these anti-stalk antibodies by single mutations than it is of escaping the other four antibodies.

The selected mutations are near the binding footprints of the antibodies

Antigenic mutations selected by narrow strain-specific antibodies against HA are thought to occur at residues in or near the physical binding footprint of the antibody (Yewdell et al., 1979; Webster and Laver, 1980; Caton et al., 1982). We examined whether this was the case for the broad antibodies used in our experiments. Figure 5A shows a zoomed-in view of the sites of mutations selected by each antibody, as well as their locations on HA's structure. It is immediately clear that the selected mutations are nearly all in or close to the antibody-binding footprint.

For the broad anti-receptor binding pocket antibody S139/1, there are strong escape mutations at sites 156, 158, and 193 (Figure 5A; sites are in H3 numbering). These three sites fall directly in the physical binding footprint of the antibody (Lee et al., 2012), and are the same three sites where Yoshida et al. (2009) selected escape
Figure 5: Mutations selected by broad and narrow antibodies. (A) Logo plots show sites where mutations have the largest effect. Letter heights are proportional to the excess fraction of virions with that mutation that survive antibody, as indicated by the scale bars. Structures are colored white to red by the excess fraction surviving for the largest-effect mutation at each site, with each antibody scaled separately. (B) Sites of selection from anti-stalk antibodies, with the same coloring scale for both antibodies. Selection for serine or threonine at sites 280 and 291 introduces glycosylation sites at 278 and 289, respectively. (C) Cladogram of group 1 HA subtypes. The amino acid at site 38 is indicated. Colors indicate whether a subtype has been reported in the literature to be bound or neutralized by C179.
mutants in H1, H2, and H3 HAs. Our data show that numerous different amino-acid mutations at each site confer neutralization resistance. The mutation with the largest effect, G158N, introduces an N-linked glycosylation motif.

Although the anti-stalk antibodies C179 and FI6v3 only select mutations with small effects, these mutations almost all fall in or near the physical binding footprints of the antibodies (Figure 5A). The two antibodies have similar epitopes and angles of approach (Dreyfus et al., 2013), and they select identical mutations at several sites (Figure 5B). The three largest-effect mutations for FI6v3 (K280S, K280T, and N291S) all introduce glycosylation motifs near the epitope, and all three mutations have similar magnitude antigenic effects in both FI6v3 and C179.

However, C179 selects several mutations that do not have any apparent effect on FI6v3 (Figure 5A, Figure S6). The most notable of these C179-specific mutations are at site 38. The additional breadth of FI6v3 over antibodies such as C179 that neutralize only group 1 HAs is because FI6v3 can accommodate a glycan on the asparagine at site 38 that is present in group 2 HAs (Corti et al., 2011; Sui et al., 2009; Ekiert et al., 2009). However, the H38S mutation that has the largest effect on C179 resistance in our experiments does not introduce a glycosylation motif, showing that there are also other ways to escape anti-stalk antibodies at this site. Interestingly, group 1 HA subtypes that are susceptible to C179 tend to possess a histidine at site 38, but subtypes that are not bound or neutralized by C179 often possess a serine (Figure 5C).

The FI6v3 antibody also weakly selects several mutations at residue -8, which is part of HA’s signal peptide (Figure 5A). This signal peptide is cleaved from the mature HA protein (Daniels et al., 2003; Burke and Smith, 2014), although mutations at this site can affect HA’s expression level (Nordholm et al., 2017).

Neutralization assays validate the mutational antigenic profiling

Do the mutations identified in our mutational antigenic profiling actually have the expected effect on antibody neutralization? We have previously validated many of the large-effect antigenic mutations selected by the narrow antibodies H17-L19, H17-L10, and H17-L7 (Doud et al., 2017). However, the mutations selected by the broad anti-stalk antibodies have much smaller effects – especially for the broadest antibody, FI6v3. We therefore tested some of these FI6v3-selected mutations using neutralization assays on individual viral mutants.

Figure 6 shows that the mutational antigenic profiling is highly predictive of the results of the neutralization assays, even for small-effect mutations. As discussed in
the previous section, the three mutations most strongly selected by FI6v3 introduce glycosylation motifs at sites 278-280 or 289-291 (Figure 5A,B). We created viruses carrying each of these mutations (K280S, K280T, and N291S) and validated that all three modestly increased resistance to FI6v3 (Figure 6A). As a control, we also validated that a mutation at one of these sites (K280A) that does not have an effect in our mutational antigenic profiling does not shift the neutralization curve (Figure 6A).

Our mutational antigenic profiling also identified several non-glycosylation-motif mutations that were selected by FI6v3. We validated that one of these mutations,

Figure 6: The mutations selected by FI6v3 increase neutralization resistance, but the effects are small. (A) Neutralization curves of individual viral mutants with FI6v3. The mutations K280S, K280T, N291S, G47R (HA2), and K(-8)T are all expected to increase neutralization resistance based on the mutational antigenic profiling (Figure 5A). The mutations K280A, M17L (HA2), P80D, and V135T are not expected to affect neutralization based on the mutational antigenic profiling (Figure S6). (B), (C) In contrast to FI6v3, mutations selected by narrow antibodies have very large effects on neutralization. Shown are neutralization curves for representative escape mutants from H17-L19 and H17-L7 taken from Doud et al. (2017).
G47R in the HA2 chain, increased neutralization resistance (Figure 6A) – although as predicted by the mutational antigenic profiling, the magnitude of the effect was small. The most unexpected mutations identified in our mutational antigenic profiling were at site -8 in the signal peptide. We tested one of these mutations, K(-8)T, and found that it did appear to lead to a very slight increase in neutralization resistance (Figure 6A). As controls, we also tested three mutations (P80D and V135T, which are escape mutations for H17-L7 and H17-L19, and M17L in HA2) that did not have substantial effects in the mutational antigenic profiling, and confirmed that none of them affected neutralization resistance.

A notable aspect of these validation experiments is the very small effect sizes of the identified mutations on neutralization by FI6v3. Antigenic mutations selected by strain-specific antibodies to HA generally increase the concentration of antibody needed to neutralize the virus by orders of magnitude. Neutralization curves for such large-effect escape mutants are in Figure 6B,C. Although there are no such large-effect single mutations that escape FI6v3 or C179, the results in Figure 6A show that we can still use mutational antigenic profiling to identify mutations that have small but measurable effects on resistance to these antibodies.

**Limited HA mutational tolerance does not fully explain the lack of strong escape mutations from the anti-stalk antibodies**

Why are there no large-effect escape mutations from the anti-stalk antibodies? One possibility is that all HA sites in the antibody-binding footprint are intolerant of mutations, meaning that viruses with mutations at these sites cannot replicate and so are not present in our mutant virus libraries. Another possibility is that mutations are tolerated at some HA sites in the antibody footprint, but that the binding energetics are distributed across sites in such a way that none of these tolerated mutations strongly affect neutralization.

We can examine these possibilities using deep mutational scanning data that measures the tolerance of HA for each possible amino-acid mutation. Specifically, we have previously selected our A/WSN/1933 virus HA mutant libraries for variants that can replicate in cell culture, and then used deep sequencing to estimate the preference of each site in HA for each possible amino acid (Doud and Bloom, 2016). Figure 7 shows these amino-acid preferences for all sites in HA within 4 angstroms of each broad antibody, with the antigenic effects of the mutations overlaid. Although some HA sites in the antibody footprints strongly prefer a single amino acid, for all antibodies there
The broad anti-stalk antibodies appear to distribute their binding energetics in such a way that altering the mutationally tolerant HA sites has relatively little effect on neutralization.
DISCUSSION

We have quantified how all single amino-acid mutations to influenza virus HA affect neutralization by a collection of broad and narrow antibodies. Our results show that the virus’s inherent evolutionary capacity for escape via point mutations differs across antibodies. Interestingly, antibody breadth is not always an indicator of the difficulty of viral escape. As expected, single amino-acid mutations can make the virus completely resistant to narrow strain-specific antibodies against HA’s globular head. However, such mutations can also enable the virus to escape the broad S139/1 antibody targeting HA’s receptor-binding pocket, despite the fact that this antibody neutralizes multiple subtypes. But no single mutation has a comparably large effect on neutralization by two broad antibodies targeting HA’s stalk, FI6v3 and C179. Therefore, these anti-stalk antibodies are quantifiably more difficult for the virus to escape.

Although there are no large-effect escape mutations from the broad anti-stalk antibodies, there are mutations that more modestly affect neutralization. This finding emphasizes the importance of identifying antigenic mutations in a way that accounts for effect sizes. The classic approach for selecting escape mutations involves treating a virus stock with antibody at a concentration that completely neutralizes wildtype, and looking for viral mutants that survive this treatment (Yewdell et al., 1979; Webster and Laver, 1980). There are no such single mutations for the HA and broad anti-stalk antibodies tested here, since no mutations shift the neutralization curve enough to enable survival at antibody concentrations that fully neutralize wildtype. However, our approach shows that there are mutations that have more modest (<10-fold) effects on neutralization by even the broadest antibody.

It is important to note that our experiments examine single amino-acid mutations to the HA from one influenza virus strain. The protein evolution literature is full of examples of epistatic interactions that enable multiple mutations to access phenotypes not accessible by single mutations (Gong et al., 2013; Harms and Thornton, 2014; Starr et al., 2017). Such epistasis is relevant to HA’s evolution. For instance, work by Das et al. (2013) suggests that the sequential accumulation of mutations can shift the spectrum of available antibody-escape mutations. Wu et al. (2017) have used deep mutational scanning to directly demonstrate that rampant epistasis enables HA’s receptor-binding pocket to accommodate combinations of individually deleterious mutations, some of which affect sensitivity to antibodies. Therefore, our work does not imply any absolute limits on the possibilities for antibody escape when evo-
olution is given sufficient time to explore combinations of mutations. However, single mutations are the most accessible form of genetic variation, and much of influenza virus’s natural antigenic drift involves individual mutations that reduce sensitivity to immunodominant antibody specificities (Yewdell et al., 1979; Webster and Laver, 1980; Koel et al., 2013; Chambers et al., 2015; Petrie et al., 2016; Neher et al., 2016). Quantifying the antigenic effects of all such mutations therefore provides a relevant measure of ease of viral antibody escape.

A major rationale for studying broadly neutralizing antibodies is that they are hoped to be more resistant to viral evolutionary escape than the antibodies that dominate natural immune responses to influenza virus (Krammer and Palese, 2015; Corti et al., 2017). We have used a new approach to quantify the extent to which this is actually true, and shown that the anti-viral activity of broad anti-stalk antibodies is indeed more – although certainly not completely – resistant to erosion by viral point mutations. Going forward, we suggest that quantifying the ease of viral escape will be a useful complement to more traditional techniques that characterize the structural epitopes and strain breadth of anti-viral antibodies.
METHODS

Antibodies

C179 IgG was purchased from Takara Bio Inc (Catalog #M145). FI6v3 was purified from 293F cells transduced with a lentiviral vector encoding a commercially synthesized gene for the IgG form of the antibody, with the heavy and light chains reverse-translated from the protein sequence in the PDB structure 3ZTN (Corti et al., 2011) as described in Balazs et al. (2013). Genes encoding S139/1 in IgG form were were reverse-translated from the protein sequence in PDB structure 4GMS (Lee et al., 2012), and used to express and purify protein by the Fred Hutchinson Cancer Research Center protein expression core.

Neutralization assays

We performed neutralization assays using influenza viruses that carried GFP in the PB1 segment. These PB1flank-eGFP were generated in co-cultures of 293T-CMV-PB1 and MDCK-SIAT1-CMV-PB1 cells as described in Bloom et al. (2010), using the standard bi-directional pHW181-PB2, ..., pHW188-NS reverse-genetics plasmids (Hoffmann et al., 2000) for all genes except PB1, plus the pHH-PB1flank-eGFP plasmid (Bloom et al., 2010). Each mutant was generated by repeating this process using a version of the pHW184-HA plasmid that had been engineered by site-directed mutagenesis to carry the indicated mutation. The neutralization assays themselves were performed by using a plate reader to quantify the GFP signal produced by MDCK-SIAT1-CMV-PB1 cells infected by PB1flank-eGFP virus that had been incubated with the indicated antibody concentration as described in Hooper and Bloom (2013). All neutralization curves represent the mean and standard deviation of three measurements.

H3 sequence numbering

Unless otherwise indicated, all residues are numbered in the H3 numbering scheme, with the signal peptide in negative numbers, the HA1 subunit as plain numbers, and the HA2 subunit denoted with “(HA2)”. The conversion between sequential numbering of the A/WSN/1933 HA and the H3 numbering scheme was performed using the Python script available at https://github.com/jbloomlab/HA_numbering. File S1 gives the numbering conversion.

Inference of HA phylogenetic tree

To infer the phylogenetic tree in Figure 2, we downloaded one HA sequence per subtype from the Influenza Research Database (Zhang et al., 2017), inferred the phylogenetic tree using RaxML (Stamatakis, 2014) with a GTR model, and visualized the tree using FigTree (http://tree.bio.ed.ac.uk/software/figtree/). The HA sequences used are in File S2. In Figure 2, we indicate which HAs each antibody has been reported to bind or neutralize (Yoshida et al., 2009; Lee et al., 2012; Okuno et al., 1993; Dreyfus et al., 2013; Corti et al., 2011). Among broad
antibodies, S139/1 has not been tested against H8, H9, and H11; C179 has not been tested against H8 and H11; and no antibodies have been tested against H17 and H18. The narrow H17-L19, H17-L10, and H17-L7 antibodies have not been tested against any other subtypes – however, since these antibodies have a very limited range even among H1 HAs (Caton et al., 1982), we assume that they do not bind other subtypes.

For the cladogram in Figure 5C, the amino-acid identities at site 38 are from the strains tested against C179 by Dreyfus et al. (2013). For subtypes not tested, the amino-acid identity reported is that in the strain for that subtype in File S2.

**Mutant virus libraries**

The mutant virus libraries are those described in Doud and Bloom (2016), and were produced in full biological triplicate. Briefly, these libraries were generated by using codon mutagenesis (Bloom, 2014) to introduce random codon mutations into plasmid-encoded HA, and then using a helper-virus strategy that avoids the bottlenecks associated with standard influenza reverse genetics to create the virus libraries. Full details of the library generation and sequencing statistics that quantify how completely each of the triplicate libraries covers the possible amino-acid mutations are in Doud and Bloom (2016).

**Mutational antigenic profiling**

The mutational antigenic profiling was performed as described in Doud et al. (2017). Briefly, we diluted each of the virus libraries to a concentration of $10^6$ TCID$_{50}$ per ml and incubated the virus dilutions with an equal volume of antibody at the intended concentration at 37°C for 1.5 hours. The final antibody concentrations in these mixtures are shown in Figure 3. We performed three fully independent replicates of each selection using the three replicate mutant virus libraries. In addition, we performed technical replicates (independent neutralization experiments on the same virus library) in some cases as indicated in Figure S1. The virus–antibody mixtures were used to infect cells, and viral RNA was extracted, reverse-transcribed, and PCR amplified as described in Doud et al. (2017). In order to obtain high accuracy in the Illumina deep sequencing, we used the barcoded-subamplicon sequencing strategy described in Doud et al. (2017), which is a slight modification of the strategy of Wu et al. (2014).

We also estimated the overall fraction of virions surviving each antibody selection. These fractions are denoted by $\gamma$ in this paper. The average of these fractions across libraries are reported in Figure 3, and the values for each individual replicate are in Table S1. The fractions were estimated using qRT-PCR against the viral NP and canine GAPDH as described in Doud et al. (2017). Briefly, we made duplicate 10-fold serial dilutions of each of the virus libraries to use as a standard curve of infectivity. We also performed qPCR on the cells infected with the virus-antibody mix. To estimate the fractions, we used linear regression to fit a line relating logarithm of the viral infectious dose in the standard curve to the difference in Ct values between NP and GAPDH, and then interpolated the fraction surviving for each selection from
this regression.

**Analysis of deep sequencing data**

The deep sequencing data were analyzed using version 2.1.0 of the dms_tools2 software package (Bloom, 2015), which is available at [http://jbloomlab.github.io/dms_tools2](http://jbloomlab.github.io/dms_tools2). File S3 contains a Jupyter notebook that performs all steps of the analysis beginning with downloading the FASTQ files from the Sequence Read Archive. Detailed statistics about the sequencing depth and error rates are shown in this Jupyter notebook.

**Calculating the fraction of virions with each mutation that escapes antibody neutralization**

In prior mutational antigenic profiling work (Doud et al., 2017; Dingens et al., 2017), we calculated the differential selection on each mutation as the logarithm of its enrichment relative to wildtype in an antibody-selected sample versus a mock-selected control. These *mutation differential selection* values are useful for the analysis of individual experiments. However, there is no natural way to compare these values across experiments with different antibodies at different concentrations, since the strength of differential selection depends on details of how the pressure is imposed. We therefore developed the new approach in this paper to quantify the antigenic effect of a mutation in units that can be compared across antibodies and concentrations.

The general principle of the calculations is illustrated in Figure 1 and discussed in the first section of the RESULTS. Here we provide details on how these calculations are performed. The deep sequencing measures the number of times that codon $x$ is observed at site $r$ in both the antibody-selected and mock-selected conditions. Denote these counts as $n_{r,x}^{\text{selected}}$ and $n_{r,x}^{\text{mock}}$, respectively. We also perform deep sequencing of a control (in this case, plasmid DNA encoding the wildtype HA gene) to estimate the sequencing error rate. Denote the counts of codon $x$ at site $r$ in this control as $n_{r,x}^{\text{err}}$. Also denote the total reads at each site $r$ in each sample as $N_{r}^{\text{selected}} = \sum_{x} n_{r,x}^{\text{selected}}$, $N_{r}^{\text{mock}} = \sum_{x} n_{r,x}^{\text{mock}}$, and $N_{r}^{\text{err}} = \sum_{x} n_{r,x}^{\text{err}}$.

We first estimate the rate of sequencing errors at site $r$ as

$$
\epsilon_{r,x} = \frac{n_{r,x}^{\text{err}}}{N_{r}^{\text{err}}}.
$$

For the wildtype identity at site $r$, which we denote as $\text{wt}(r)$, the value of $\epsilon_{r,\text{wt}(r)}$ is the fraction of times we correctly observe the wildtype identity $\text{wt}(r)$ at site $r$ versus observing some spurious mutation. For all mutant identities $x \neq \text{wt}(r)$ at site $r$, $\epsilon_{r,x}$ is the fraction of times we observe the mutation $x$ at site $r$ when the identity is really wildtype. We ignore second-order terms where we incorrectly read one mutation as another, as such errors will be very rare as mutations themselves are rare (most codons are wildtype in most sequences).

We next adjust all of the deep sequencing codon counts in the antibody-selected and
mock-selected conditions by the error control. Specifically, the error-adjusted counts for the antibody-selected sample are

\[
\hat{n}_{r,x}^{\text{selected}} = \begin{cases} 
\max \left[ N_r^{\text{selected}} \times \left( \frac{n_{r,x}^{\text{selected}}}{N_r^{\text{selected}}} - \epsilon_{r,x} \right), 0 \right] & \text{if } x \neq \text{wt}(r) \\
\frac{n_{r,x}}{\epsilon_{r,x}} & \text{if } x = \text{wt}(r).
\end{cases}
\] (4)

An equivalent equation is used to calculate \( \hat{n}_{r,x}^{\text{mock}} \). We then sum the error-adjusted codon counts for each amino acid \( a \):

\[
\hat{n}_{r,a}^{\text{selected}} = \sum_{\{x | A(x) = a\}} \hat{n}_{r,x}^{\text{selected}},
\] (5)

so that \( \hat{n}_{r,a}^{\text{selected}} \) are the error-adjusted counts for the antibody-selected condition summed across all codons \( x \) where the encoded amino acid \( A(x) \) is \( a \). An equivalent equation is used to calculate \( \hat{n}_{r,a}^{\text{mock}} \).

Finally, we use these error-adjusted amino-acid counts to estimate the mutation frequencies \( \rho_{r,a}^{\text{selected}} \) and \( \rho_{r,a}^{\text{mock}} \) that are used in Equation 1 to calculate the fraction \( F_{r,a} \) of virions with amino acid \( a \) at site \( r \) that survive the selection. When estimating these mutation frequencies, we add a pseudocount of \( P = 5 \) to the lower-depth sample, and a depth-adjusted pseudocount to the higher depth sample. The rationale for adding a pseudocount is to regularize the estimates in the case of low counts. Specifically, we estimate the mutation frequencies as

\[
\rho_{r,x}^{\text{selected}} = \frac{n_{r,x}^{\text{selected}} + f_{r,\text{selected}} \times P}{N_r^{\text{selected}} + f_{r,\text{selected}} \times P \times A}
\] (6)

\[
\rho_{r,x}^{\text{mock}} = \frac{n_{r,x}^{\text{mock}} + f_{r,\text{mock}} \times P}{N_r^{\text{mock}} + f_{r,\text{mock}} \times P \times A}
\] (7)

where \( A \) is the number of characters (e.g., 20 for amino acids), \( f_{r,\text{selected}} \) and \( f_{r,\text{mock}} \) are the pseudocount adjustment factors defined as:

\[
f_{r,\text{selected}} = \max \left( 1, \frac{N_r^{\text{selected}}}{N_r^{\text{mock}}} \right)
\] (8)

\[
f_{r,\text{mock}} = \max \left( 1, \frac{N_r^{\text{mock}}}{N_r^{\text{selected}}} \right)
\] (9)

The pseudocount adjustment factors ensure that \( P \) is added to the counts for the lower depth sample, and a proportionally scaled-up pseudocount is added to the higher depth sample. The depth scaling is necessary to avoid systematically biasing towards higher mutation frequencies in the lower depth sample. It is these estimated mutation frequencies that are used in conjunction with \( \gamma \) (the qPCR estimated overall of virions that survive selection) to compute the fraction surviving \( (F_{r,a}) \) and excess fraction surviving above the library average \( (F_{r,a}^{\text{excess}}) \) via Equations 1 and 2.
In some cases, we need to summarize the excess fraction of mutations surviving into a single number for each site, such as for plotting as a function of the site number or displaying on the crystal structure. There are 19 different $F_{r,a}^{\text{excess}}$ values for non-wildtype amino acids for each site. One summary statistic is the fraction surviving above the library average averaged over all 19 amino-acid mutations at site $r$:

$$F_{r}^{\text{avg}} = \frac{1}{19} \sum_{\{a|a\neq \text{wt}(r)\}} F_{r,a}^{\text{excess}}.$$ (10)

Another summary statistic is the maximum fraction surviving above average among all 19 amino-acid mutations at site $r$:

$$F_{r}^{\text{max}} = \frac{1}{19} \max_{\{a|a\neq \text{wt}(r)\}} \left( F_{r,a}^{\text{excess}} \right).$$ (11)

In this paper, Figures 4 and S2 show the median of excess fraction surviving taken across all biological and technical replicates at a given antibody concentration. The subsequent logo plots show the medians of these values taken across all concentrations for each antibody. The numerical values plotted in these logo plots are in File S4.

Code that performs these fraction surviving analyses has been added to version 2.1.0 of the dms_tools2 software package (Bloom, 2015) which is available at http://jbloomlab.github.io/dms_tools2.

**Data availability and source code**

Deep sequencing data are available from the Sequence Read Archive under BioSample accession SAMN05789126. Computer code that analyzes these data to generate the results described in this paper is in File S3.

**ACKNOWLEDGMENTS**

We thank Adam Dingens, Sarah Hilton, Katherine Xue, Lauren Gentles, and Jeremy Roop for helpful comments on the project and manuscript. We thank the Fred Hutchinson Cancer Research Center genomics core for performing the Illumina deep sequencing, and the protein expression core for expressing and purifying the C179 antibody. This work was supported by grant R01AI127893 from the NIAID of the NIH. MBD was supported in part by training grant T32AI083203 from the NIAID of the NIH. JML was supported in part by the Center for Inference and Dynamics of Infectious Diseases (CIDID), which is funded by grant U54GM111274 from the NIGMS of the NIH. The research of JDB is supported in part by a Faculty Scholar Grant from the Howard Hughes Medical Institute and the Simons Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
AUTHOR CONTRIBUTIONS

MBD and JML performed the experiments. All three authors designed the project, contributed to the computer code, analyzed the data, and wrote the paper.

References

Andrews S, Huang Y, Kaur K, et al. (11 co-authors). 2015. Immune history profoundly affects broadly protective B cell responses to influenza. *Science Translational Medicine*. 7:316ra192.

Balazs AB, Bloom JD, Hong CM, Rao DS, Baltimore D. 2013. Broad protection against influenza infection by vectored immunoprophylaxis in mice. *Nature Biotechnology*. 31:647–652.

Birrer MJ, Udem S, Nathenson S, Bloom BR. 1981. Antigenic variants of measles virus. *Nature*. 293:67–69.

Bloom JD. 2014. An experimentally determined evolutionary model dramatically improves phylogenetic fit. *Molecular Biology and Evolution*. 31:1956–1978.

Bloom JD. 2015. Software for the analysis and visualization of deep mutational scanning data. *BMC Bioinformatics*. 16:1.

Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. *Science*. 328:1272–1275.

British Medical Journal. 1978. Influenza in a boarding school. *British Medical Journal*. 1:587.

Burke DF, Smith DJ. 2014. A recommended numbering scheme for influenza A HA subtypes. *PloS One*. 9:e112302.

Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. 1982. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). *Cell*. 31:417–427.

Cattoli G, Milani A, Temperton N, Zecchin B, Buratin A, Molesti E, Meherez Aly M, Arafa A, Capua I, et al. (10 co-authors). 2011. Antigenic drift in H5N1 avian influenza virus in poultry is driven by mutations in major antigenic sites of the hemagglutinin molecule analogous to those for human influenza virus. *Journal of Virology*. 85:8718–8724.

Chai N, Swem LR, Reichelt M, et al. (11 co-authors). 2016. Two escape mechanisms of influenza A virus to a broadly neutralizing stalk-binding antibody. *PLoS Pathogens*. 12:e1005702.

Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. 2015. Identification of hemagglutinin residues responsible for H3N2 antigenic drift during the 2014–2015 influenza season. *Cell Reports*. 12:1–6.
Cobey S. 2014. Pathogen evolution and the immunological niche. *Annals of the New York Academy of Sciences*. 1320:1–15.

Corti D, Cameroni E, Guarino B, Kallewaard NL, Zhu Q, Lanzavecchia A. 2017. Tackling influenza with broadly neutralizing antibodies. *Current Opinion in Virology*. 24:60–69.

Corti D, Voss J, Gamblin SJ, et al. (11 co-authors). 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. *Science*. 333:850–856.

Couch RB, Kasel JA. 1983. Immunity to influenza in man. *Annual Reviews in Microbiology*. 37:529–549.

Crainic R, Couillin P, Blondel B, Cabau N, Boue A, Horodniceanu F. 1983. Natural variation of poliovirus neutralization epitopes. *Infection and Immunity*. 41:1217–1225.

Cunningham BC, Wells JA. 1993. Comparison of a structural and a functional epitope. *Journal of Molecular Biology*. 234:554–563.

Dall’Acqua W, Goldman ER, Lin W, et al. (11 co-authors). 1998. A mutational analysis of binding interactions in an antigen-antibody protein-protein complex. *Biochemistry*. 37:7981–7991.

Daniels R, Kurowski B, Johnson AE, Hebert DN. 2003. N-linked glycans direct the cotranslational folding pathway of influenza hemagglutinin. *Molecular cell*. 11:79–90.

Das SR, Hensley SE, Ince WL, Brooke CB, Subba A, Delboy MG, Russ G, Gibbs JS, Bennink JR, Yewdell JW. 2013. Defining influenza a virus hemagglutinin antigenic drift by sequential monoclonal antibody selection. *Cell Host & Microbe*. 13:314–323.

Davies J, Smith A, Grilli E, Hoskins T. 1982. Christ’s hospital 1978–79: An account of two outbreaks of influenza a h1n1. *Journal of Infection*. 5:151–156.

Diamond DC, Jameson BA, Bonin J, et al. (11 co-authors). 1985. Antigenic variation and resistance to neutralization in poliovirus type 1. *Science*. 229:1090–1093.

Dingens AS, Haddox HK, Overbaugh J, Bloom JD. 2017. Comprehensive mapping of HIV-1 escape from a broadly neutralizing antibody. *Cell Host & Microbe*. 21:777–787.

Doud MB, Bloom JD. 2016. Accurate measurement of the effects of all amino-acid mutations to influenza hemagglutinin. *Viruses*. 8:155.

Doud MB, Hensley SE, Bloom JD. 2017. Complete mapping of viral escape from neutralizing antibodies. *PLoS Pathogens*. 13:e1006271.
Drexler JF, Grard G, Lukashev AN, et al. (11 co-authors). 2014. Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. *Proceedings of the National Academy of Sciences*. 111:12889–12894.

Dreyfus C, Ekiert DC, Wilson IA. 2013. Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin. *Journal of Virology*. 87:7149–7154.

Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, Goudsmit J, Wilson IA. 2009. Antibody recognition of a highly conserved influenza virus epitope. *Science*. 324:246–251.

Ekiert DC, Kashyap AK, Steel J, et al. (18 co-authors). 2012. Cross-neutralization of influenza viruses mediated by a single antibody loop. *Nature*. 489:526–532.

Ellebedy AH, Krammer F, Li GM, et al. (11 co-authors). 2014. Induction of broadly cross-reactive antibody responses to the influenza ha stem region following H5N1 vaccination in humans. *Proceedings of the National Academy of Sciences*. 111:13133–13138.

Fulton BO, Sachs D, Beaty SM, Won ST, Lee B, Palese P, Heaton NS. 2015. Mutational analysis of measles virus suggests constraints on antigenic variation of the glycoproteins. *Cell Reports*. 11:1331–1338.

Gamblin S, Haire L, Russell R, et al. (11 co-authors). 2004. The structure and receptor binding properties of the 1918 influenza hemagglutinin. *Science*. 303:1838–1842.

Gong LI, Suchard MA, Bloom JD. 2013. Stability-mediated epistasis constrains the evolution of an influenza protein. *eLife*. 2:e00631.

Harms MJ, Thornton JW. 2014. Historical contingency and its biophysical basis in glucocorticoid receptor evolution. *Nature*. 512:203–207.

Heaton NS, Sachs D, Chen CJ, Hai R, Palese P. 2013. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. *Proceedings of the National Academy of Sciences*. 110:20248–20253.

Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. *Proc. Natl. Acad. Sci. USA*. 97:6108–6113.

Hooper KA, Bloom JD. 2013. A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein. *Journal of Virology*. 87:12531–12540.

Jin L, Fendly BM, Wells JA. 1992. High resolution functional analysis of antibody-antigen interactions. *Journal of Molecular Biology*. 226:851–865.
Koel BF, Burke DF, Bestebroer TM, et al. (11 co-authors). 2013. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. *Science*. 342:976–979.

Krammer F, Palese P. 2015. Advances in the development of influenza virus vaccines. *Nature Reviews Drug Discovery*. 14:167–182.

Lee CW, Senne DA, Suarez DL. 2004. Effect of vaccine use in the evolution of mexican lineage H5N2 avian influenza virus. *Journal of Virology*. 78:8372–8381.

Lee PS, Yoshida R, Ekiert DC, Sakai N, Suzuki Y, Takada A, Wilson IA. 2012. Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. *Proceedings of the National Academy of Sciences*. 109:17040–17045.

Lipsitch M, O’Hagan JJ. 2007. Patterns of antigenic diversity and the mechanisms that maintain them. *Journal of the Royal Society Interface*. 4:787–802.

Luoh S, McGregor M, Hinshaw V. 1992. Hemagglutinin mutations related to antigenic variation in H1 swine influenza viruses. *Journal of Virology*. 66:1066.

Neher RA, Bedford T, Daniels RS, Russell CA, Shraiman BI. 2016. Prediction, dynamics, and visualization of antigenic phenotypes of seasonal influenza viruses. *Proceedings of the National Academy of Sciences*. 113:E1701–E1709.

Nordholm J, Petitou J, Östbye H, da Silva DV, Dou D, Wang H, Daniels R. 2017. Translational regulation of viral secretory proteins by the 5 coding regions and a viral RNA-binding protein. *J Cell Biol*. 216:2283–2293.

Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. *Journal of Virology*. 67:2552–2558.

Panum PL. 1847. Iagttagelser, anstillede under Maesllinge-Epidemien paa Faeroerne i Aaret 1846:(Observations made during the epidemic of measles on the Faroe Islands in the year 1846), volume 3. Bibliothek for Laeger.

Petrie JG, Parkhouse K, Ohmit SE, Malosh RE, Monto AS, Hensley SE. 2016. Antibodies against the current influenza A (H1N1) vaccine strain do not protect some individuals from infection with contemporary circulating influenza A (H1N1) virus strains. *The Journal of Infectious Diseases*. 214:1947–1951.

Salk J. 1984. One-dose immunization against paralytic poliomyelitis using a noninfectious vaccine. *Reviews of Infectious Diseases*. 6:S444–S450.
Schmidt AG, Therkelsen MD, Stewart S, Kepler TB, Liao HX, Moody MA, Haynes BF, Harrison SC. 2015. Viral receptor-binding site antibodies with diverse germline origins. *Cell*. 161:1026–1034.

Sheerar M, Easterday B, Hinshaw V. 1989. Antigenic conservation of H1N1 swine influenza viruses. *Journal of General Virology*. 70:3297–3303.

Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics*. 30:1312–1313.

Starr TN, Picton LK, Thornton JW. 2017. Alternative evolutionary histories in the sequence space of an ancient protein. *Nature*. 549:409–413.

Sui J, Hwang WC, Perez S, et al. (11 co-authors). 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. *Nature Structural & Molecular Biology*. 16:265–273.

Ter Meulen V, Löffler S, Carter MJ, Stephenson JR. 1981. Antigenic characterization of measles and SSPE virus haemagglutinin by monoclonal antibodies. *Journal of General Virology*. 57:357–364.

Thyagarajan B, Bloom JD. 2014. The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. *eLife*. 3:e03300.

Webster R, Laver W. 1980. Determination of the number of nonoverlapping antigenic areas on Hong Kong (H3N2) influenza virus hemagglutinin with monoclonal antibodies and the selection of variants with potential epidemiological significance. *Virology*. 104:139–148.

Wu NC, Xie J, Zheng T, Nycholat CM, Grande G, Paulson JC, Lerner RA, Wilson IA. 2017. Diversity of functionally permissive sequences in the receptor-binding site of influenza hemagglutinin. *Cell Host & Microbe*. 21:742–753.

Xue KS, Stevens-Ayers T, Campbell AP, Englund JA, Pergam SA, Boeckh M, Bloom JD. 2017. Parallel evolution of influenza across multiple spatiotemporal scales. *eLife*. 6:e26875.

Yewdell J, Webster R, Gerhard W. 1979. Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule. *Nature*. 279:246–248.

Yoshida R, Igarashi M, Ozaki H, Kishida N, Tomabechi D, Kida H, Ito K, Takada A. 2009. Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses. *PLoS Pathogens*. 5:e1000350.
Yu X, Tsibane T, McGraw PA, et al. (11 co-authors). 2008. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. *Nature*. 455:532.

Zhang Y, Aevermann B, Anderson T, et al. (11 co-authors). 2017. Influenza Research Database: An integrated bioinformatics resource for influenza virus research. *Nucleic Acids Research*. 45:D466–D474.
Figure S1: Correlations across experimental replicates. Each point represents one site in HA, and gives the fraction surviving above average across all amino-acid mutations at that site, as calculated using Equation 10. The replicates are highly correlated for antibodies with strong escape mutations (S139/1, H17-L19, H17-L10, and H17-L7), and reasonably correlated for antibodies with only weak escape mutations (Fl6v3 and C179).
Figure S2: The excess fraction surviving for the single strongest escape mutation at each site. This plot differs from Figure 4 in that the height of the line indicates the excess fraction of virions that survive the antibody selection for the single strongest escape mutation at that site, rather than the average across all amino-acid mutations at that site.
Figure S3: The excess fraction surviving selection with antibody H17L19 for all amino-acid mutations. The excess fraction surviving for each replicate was computed using Equation 2, then we took the median across all technical and biological replicates for each antibody concentration, and then took the medians of those values across concentrations. The height of each letter is proportional to the excess fraction surviving of virions with that mutation. The scale bar at the top of the plot relates the letter heights to the actual fractions. The sites are labeled using H3 numbering.
Figure S4: The excess fraction surviving selection with antibody H17L10 for all amino-acid mutations. The excess fraction surviving for each replicate was computed using Equation 2, then we took the median across all technical and biological replicates for each antibody concentration, and then took the medians of those values across concentrations. The height of each letter is proportional to the excess fraction surviving of virions with that mutation. The scale bar at the top of the plot relates the letter heights to the actual fractions. The sites are labeled using H3 numbering.
Fraction surviving = 0.5

Figure S5: The excess fraction surviving selection with antibody H17L7 for all amino-acid mutations. The excess fraction surviving for each replicate was computed using Equation 2, then we took the median across all technical and biological replicates for each antibody concentration, and then took the medians of those values across concentrations. The height of each letter is proportional to the excess fraction surviving of virions with that mutation. The scale bar at the top of the plot relates the letter heights to the actual fractions. The sites are labeled using H3 numbering.
Figure S6: The excess fraction surviving selection with antibody FI6v3 for all amino-acid mutations. The excess fraction surviving for each replicate was computed using Equation 2, then we took the median across all technical and biological replicates for each antibody concentration, and then took the medians of those values across concentrations. The height of each letter is proportional to the excess fraction surviving of virions with that mutation. The scale bar at the top of the plot relates the letter heights to the actual fractions. The sites are labeled using H3 numbering.
Figure S7: The excess fraction surviving selection with antibody C179 for all amino-acid mutations. The excess fraction surviving for each replicate was computed using Equation 2, then we took the median across all technical and biological replicates for each antibody concentration, and then took the medians of those values across concentrations. The height of each letter is proportional to the excess fraction surviving of virions with that mutation. The scale bar at the top of the plot relates the letter heights to the actual fractions. The sites are labeled using H3 numbering.
Figure S8: The excess fraction surviving selection with antibody S139/1 for all amino-acid mutations. The excess fraction surviving for each replicate was computed using Equation 2, then we took the median across all technical and biological replicates for each antibody concentration, and then took the medians of those values across concentrations. The height of each letter is proportional to the excess fraction surviving of virions with that mutation. The scale bar at the top of the plot relates the letter heights to the actual fractions. The sites are labeled using H3 numbering.
| antibody | concentration (µg/ml) | replicate | fraction surviving |
|----------|-----------------------|-----------|-------------------|
| Fl6v3    | 0.1                   | 1a        | 0.01662           |
| Fl6v3    | 0.1                   | 1b        | 0.01390           |
| Fl6v3    | 0.2                   | 1a        | 0.00465           |
| Fl6v3    | 0.2                   | 1b        | 0.00345           |
| Fl6v3    | 0.1                   | 2         | 0.02322           |
| Fl6v3    | 0.2                   | 2         | 0.00278           |
| Fl6v3    | 0.1                   | 3         | 0.00903           |
| Fl6v3    | 0.2                   | 3         | 0.00144           |
| S139/1   | 100.0                 | 1         | 0.02490           |
| S139/1   | 200.0                 | 1         | 0.01470           |
| S139/1   | 300.0                 | 1         | 0.01270           |
| S139/1   | 100.0                 | 2         | 0.02190           |
| S139/1   | 200.0                 | 2         | 0.01720           |
| S139/1   | 300.0                 | 2         | 0.00854           |
| S139/1   | 100.0                 | 3         | 0.05180           |
| S139/1   | 200.0                 | 3         | 0.04060           |
| S139/1   | 300.0                 | 3         | 0.03750           |
| C179     | 1.0                   | 1a        | 0.00941           |
| C179     | 1.0                   | 1b        | 0.00890           |
| C179     | 1.0                   | 1c        | 0.00960           |
| C179     | 2.5                   | 1         | 0.00450           |
| C179     | 1.0                   | 2         | 0.00554           |
| C179     | 2.5                   | 2         | 0.00198           |
| C179     | 1.0                   | 3         | 0.00256           |
| C179     | 2.5                   | 3         | 0.00100           |

Table S1: The total fraction of virions surviving each antibody treatment at each concentration as estimated by qPCR. These are the quantities referred to as $\gamma$. This table shows the values for the broad antibodies; values for the narrow H17-L17, H17-L10, and H17-L7 antibodies are reported in Doud et al. (2017).
File S1: Conversion from sequential numbering of the A/WSN/1933 HA to H3 numbering. In this CSV file, the original column gives the residue number in sequential (1, 2, ...) numbering of the A/WSN/1933 HA, and the new column gives the residue number in H3 numbering.

File S2: Sequences used to infer the tree for all HA subtypes. This FASTA file gives the HA sequences used to infer the tree of subtypes in Figure 2.

File S3: Computer code and data for the analysis of the mutational antigenic profiling data. The code in this ZIP file performs the entire computational analysis beginning with downloading the FASTQ files from the Sequence Read Archive. The ZIP file contains a README file that explains the contents in detail. The actual analysis is performed by the Jupyter notebook analysis_notebook.ipynb, which includes embedded plots summarizing key statistics and results. An HTML version of this notebook is also included as analysis_notebook.html.

File S4: The excess fraction surviving for each mutation for each antibody. This file is a ZIP of CSV files giving the numerical values plotted in the logo plots. These are median excess fraction surviving taken first across replicates and then across antibody concentrations.